- Home
- BSAC vs EXEL Comparison
BSAC vs EXEL Comparison
Compare BSAC & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BSAC
- EXEL
- Stock Information
- Founded
- BSAC 1977
- EXEL 1994
- Country
- BSAC Chile
- EXEL United States
- Employees
- BSAC N/A
- EXEL N/A
- Industry
- BSAC Commercial Banks
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- BSAC Finance
- EXEL Health Care
- Exchange
- BSAC Nasdaq
- EXEL Nasdaq
- Market Cap
- BSAC 12.4B
- EXEL 10.4B
- IPO Year
- BSAC 1994
- EXEL 2000
- Fundamental
- Price
- BSAC $26.63
- EXEL $38.77
- Analyst Decision
- BSAC Hold
- EXEL Buy
- Analyst Count
- BSAC 2
- EXEL 22
- Target Price
- BSAC $22.50
- EXEL $44.00
- AVG Volume (30 Days)
- BSAC 273.3K
- EXEL 2.4M
- Earning Date
- BSAC 10-30-2025
- EXEL 10-28-2025
- Dividend Yield
- BSAC 3.79%
- EXEL N/A
- EPS Growth
- BSAC 88.01
- EXEL 81.76
- EPS
- BSAC 0.01
- EXEL 2.08
- Revenue
- BSAC $2,504,429,686.00
- EXEL $2,230,005,000.00
- Revenue This Year
- BSAC $41.14
- EXEL $9.19
- Revenue Next Year
- BSAC $5.30
- EXEL $12.54
- P/E Ratio
- BSAC $10.87
- EXEL $19.09
- Revenue Growth
- BSAC 38.82
- EXEL 10.73
- 52 Week Low
- BSAC $18.19
- EXEL $25.17
- 52 Week High
- BSAC $26.83
- EXEL $49.62
- Technical
- Relative Strength Index (RSI)
- BSAC 57.59
- EXEL 47.74
- Support Level
- BSAC $26.14
- EXEL $38.98
- Resistance Level
- BSAC $26.74
- EXEL $41.44
- Average True Range (ATR)
- BSAC 0.40
- EXEL 0.93
- MACD
- BSAC -0.07
- EXEL -0.06
- Stochastic Oscillator
- BSAC 64.26
- EXEL 27.35
About BSAC Banco Santander - Chile ADS
Founded in 1978, Banco Santander Chile is part of Santander Group and majority-controlled by Santander Spain. It is the largest bank in Chile by loans and the second largest by deposits. The bank generates most of its net interest income (roughly 65% of total revenue) from its mortgages, unsecured consumer credit lines, and commercial loans. Banco Santander's commercial loan business is more focused on small- to medium-size companies, with firms generating more than CLP 10,000 million in revenue only making up around 5% of outstanding loans. Outside of lending, Banco Santander is the largest card issuer in the country with around 25% of the market and benefits from a long-term strategic partnership with the largest airline in the country, LATAM.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.